Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Re-evaluation of proposed proprietary name ATryn


Date: November 18, 2008

To: Nisha Jain, OBRR/DH/LBVB, HFM-343
Pratibha Rana, OBRR/DBA/RPMB, HFM-380

From: Maryann Gallagher, Consumer Safety Officer
Advertising and Promotional Labeling Branch (APLB)
Division of Case Management (DCM), HFM-602

Though: Ele Ibarra-Pratt, RN, MPH, Branch Chief, APLB, DCM, HFM-602

Subject: Re-evaluation of proposed proprietary name ATryn (Antithrombin alfa) BLA STN 125284/0

Recommendation: Proposed proprietary name ATryn is Acceptable with concerns.

Executive Summary:

APLB found that no new information has been presented that would change our previous recommendation of Acceptable with concerns. Therefore, we recommend that the proposed proprietary name ATryn be found Acceptable with concerns. The approval date is February the 7, 2009.

Proposed Proprietary Name Evaluation:

APLB performed a re-evaluation of the proposed proprietary name, ATryn , to determine if the proposed name could be considered false, misleading, or fanciful since our previous review on March 7, 2008. APLB re-reviewed the proprietary name because substantial time had passed since our last review and to ensure that there are no newly marketed product whose name resembled Atryn within 90 days of approval.


No newly approved products whose name resembled ATryn were found. APLB recommends that the proposed proprietary name ATryn be found Acceptable with concerns, which is consistent with our March 7, 2008 review memo.

If you have any questions regarding this review, please contact Maryann Gallagher at 301-827-6330.

Page Last Updated: 08/10/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English